Loading candles…
Dr. Agarwal’s Health Care, incorporated in 2010, is a company operating in the eye care, healthcare, and ophthalmology industries. It provides a range of eye care services, including consultations, diagnostics, cataract and refractive surgeries, and non-surgical treatments. The company also sells optical products such as contact lenses and accessories, as well as pharmaceutical items related to eye care. Operating over 250 facilities across India and Africa as of late 2025, Dr. Agarwal’s Health Care employs a hub-and-spoke model to maintain clinical quality and broad accessibility. It is recognized as one of the largest eye care chains in India based on operational revenue.
This page is a live market overview for DR AGARWALS HEALTH CARE L (AGARWALEYE) on the NSE. As a listed security, DR AGARWALS HEALTH CARE L is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for AGARWALEYE before placing trades on tick2trade.
As of the latest feed, AGARWALEYE last traded at ₹546.25 on NSE, up ₹13.95 (2.62%) from the previous close of ₹532.3. Today's session range is ₹523.05 – ₹550, against a 52-week band of ₹401 – ₹568. Traded volume today stands at 1.59L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for AGARWALEYE in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether AGARWALEYE is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for DR AGARWALS HEALTH CARE L before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in AGARWALEYE. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated AGARWALEYE option chain page linked from this overview.
| Date |
|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 4 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 21 May 2026 |
| Unaudited Results - Q3 & FY25 | To consider and approve the Unaudited (Standalone & Consolidated) Financial Results of the Company for the quarter and half year ended December 31, 2025 | 3 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 12 Aug 2025 |
| Audited Results - Q4 & FY25 | To consider and approve the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2025 | 28 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.